Table 2.

Effects of rivaroxaban + aspirin vs aspirin on mace and major bleeding in patients with stable coronary artery disease according to the duration of treatment data from the compass study.

	MACE		Major Bleeding
	HR	95% CI	HR	95% CI
<1 year	0.79	0.65-0.96	2.32	1.75-3.07
1-2 years	0.66	0.52-0.83	1.19	0.84-1.68)
>2 years	0.82	0.58-1.16	1.05	0.63-1.75

Note:Table performed with data taken from reference #34.